Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy

被引：0
|
作者：
Zhenfei Li
Mohammad Alyamani
Jianneng Li
Kevin Rogacki
Mohamed Abazeed
Sunil K. Upadhyay
Steven P. Balk
Mary-Ellen Taplin
Richard J. Auchus
Nima Sharifi
机构：
[1] Lerner Research Institute,Department of Cancer Biology
[2] Cleveland Clinic,Department of Radiation Oncology
[3] Taussig Cancer Institute,Departments of Pharmacology and Internal Medicine, Division of Endocrinology and Metabolism
[4] Cleveland Clinic,Department of Urology
[5] University of Michigan Medical School,Department of Hematology and Oncology
[6] Beth Israel Deaconess Medical Center,undefined
[7] Harvard Medical School,undefined
[8] Dana-Farber Cancer Institute,undefined
[9] Harvard Medical School,undefined
[10] Glickman Urological and Kidney Institute,undefined
[11] Cleveland Clinic,undefined
[12] Taussig Cancer Institute,undefined
[13] Cleveland Clinic,undefined
来源：
Nature | 2016年 / 533卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The prostate cancer drug abiraterone can be metabolized into several substances with different effects, and optimization of this process could be helpful for fine-tuning the treatment of prostate cancer.
引用
收藏
页码：547 / 551
页数：4
相关论文
共 50 条
  • [1] Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy
    Li, Zhenfei
    Alyamani, Mohammad
    Li, Jianneng
    Rogacki, Kevin
    Abazeed, Mohamed
    Upadhyay, Sunil K.
    Balk, Steven P.
    Taplin, Mary-Ellen
    Auchus, Richard J.
    Sharifi, Nima
    NATURE, 2016, 533 (7604) : 547 - +
  • [2] Re: Redirecting Abiraterone Metabolism to Fine-Tune Prostate Cancer Anti-Androgen Therapy
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2016, 196 (05): : 1447 - 1447
  • [3] Redirecting abiraterone metabolism to biochemically fine tune prostate cancer therapy
    Li, Zhenfei
    Alyamani, Mohammad
    Sharifi, Nima
    CANCER RESEARCH, 2016, 76
  • [4] Fine tuning metabolism of biochemically active abiraterone metabolites to optimize anti-androgen therapy in prostate cancer.
    Sharifi, Nima
    Li, Zhenfei
    Alyamani, Mohammad
    Li, Jianneng
    Upadhyay, Sunil
    Balk, Steven P.
    Taplin, Mary-Ellen
    Auchus, Richard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance
    Zhang, Haozhe
    Zhou, Yi
    Xing, Zengzhen
    Sah, Rajiv Kumar
    Hu, Junqi
    Hu, Hailiang
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (21)
  • [6] Third generation anti-androgen therapy of advanced prostate cancer
    Ohlmann, C. -H.
    Kamradt, J.
    Stoeckle, M.
    UROLOGE, 2012, 51 (04): : 522 - 526
  • [7] Prevalence of osteoporosis in patients with prostate cancer on anti-androgen therapy
    Senan Sanz, M. R.
    Haro Iniesta, L.
    Riel Cabrera, R.
    Olive Ferre, F. X.
    Biel Arrufat, A.
    Matinero Romero, E.
    SWISS MEDICAL WEEKLY, 2009, 139 (33-34) : 151S - 151S
  • [8] Anti-androgen monotherapy for metastatic prostate cancer
    Attard, Gerhardt
    LANCET ONCOLOGY, 2014, 15 (06): : 543 - 544
  • [9] EFFECTS OF ANTI-ANDROGEN THERAPY ON THE METASTATIC BEHAVIOR OF PROSTATE-CANCER
    HUTCHINS, GM
    DELAMONTE, SM
    MOORE, GW
    FEDERATION PROCEEDINGS, 1984, 43 (03) : 600 - 600
  • [10] Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer
    C Sanchez
    R Chan
    P Bajgain
    S Rambally
    G Palapattu
    M Mims
    C M Rooney
    A M Leen
    M K Brenner
    J F Vera
    Prostate Cancer and Prostatic Diseases, 2013, 16 : 123 - 131
12345